Turkey Over The Counter (OTC) Analgesics Market Analysis Sample Report

Turkey Over The
Counter (OTC)
Analgesics Market
Analysis
A sample report on
www.insights10.com
Includes Market Size, Market Segmented by Types
and Key Competitors (Data forecasts from 2022 – 2030F)

This report presents a strategic analysis of the Turkey Over The
Counter (OTC) Analgesics Market and a forecast for its development
in the medium and long term. It provides a comprehensive overview of the
market value, dynamics, segmentation, main players, growth and demand
drivers, challenges & future outlook, etc. This is one of the most
comprehensive reports about the Turkey Over The Counter (OTC)
Analgesics Market, and offers unmatched value, accuracy, and expert
insights

3
A Sample Report on Turkey Over The Counter (OTC) Analgesics Market Analysis I Confidential
Report Scope
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2022
Forecast Period 2023-2030
Report Coverage
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends,
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape,
Reimbursement Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Research Approach Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology

4
Table of Content
CONTENT PG. NO.
1. Turkey Over The Counter (OTC) Analgesics Market Overview 12-25
1.1. Overview
1.2. Turkey Overview
1.3. Economic Overview: Turkey
1.4. Over The Counter (OTC) Analgesics Market Market in Turkey
1.5. Pharmaceuticals Market in Turkey
1.6. Healthcare Scenario in Turkey
1.7. Health Insurance Coverage: Turkey
1.8. Budget of the Government for Public Insurance
1.9. Mergers and Acquisitions
2. Market Size and Forecasting 36-30
2.1 Market size and forecasts (Excel and Methodology)

5
Table of Content
CONTENT PG. NO.
2.2. Market Segmentation
2.2.1. By Product
2.2.2. By Distribution
3. Market Dynamics 31-34
3.1. Market Growth Drivers
3.1.1. Turkey Over The Counter (OTC) Analgesics Market Driver 1
3.2. Market Restraints
3.2.1. Turkey Over The Counter (OTC) Analgesics Market Restraint 1

6
Table of Content
CONTENT PG. NO.
4. Competitive Landscape 35-45
4.1. Major Market Share
4.2. Key Company Profile
4.2.1. Sanovel Pharmaceuticals
4.2.1.1. Overview
4.2.1.2. Product Applications & Services
4.2.1.3. Recent Developments
4.2.1.4. Partnerships Ecosystem
4.2.1.5. Financials (Based on Availability)
4.2.2. Bilim Pharmaceuticals
4.2.2.1. Overview

7
Table of Content
CONTENT PG. NO.
4.2.3. Abdi Ibrahim IIac Sanayi ve Ticaret
4.2.3.1. Overview
4.2.4. Novartis
4.2.4.1. Overview

8
Table of Content
CONTENT PG. NO.
4.2.5. GlaxoSmithKline
4.2.5.1. Overview
4.2.6. Johnson and Johnson
4.2.6.1. Overview

9
Table of Content
CONTENT PG. NO.
4.2.7. Bayer AG
4.2.7.1. Overview
4.2.8. Reckitt Benckiser Group
4.2.8.1. Overview

10
Table of Content
CONTENT PG. NO.
4.2.9. Pfizer
4.2.9.1. Overview
4.2.10. Bohringer Ingelheim International
4.2.10.1. Overview

11
Table of Content
CONTENT PG. NO.
5. Reimbursement Scenario 46-51
5.1. Reimbursement Regulation
5.2. Reimbursement Process for Diagnosis
5.3. Reimbursement Process for Treatment
6. Methodology & Scope 52

Turkey Over The Counter (OTC) Analgesics Market Analysis
1. Over The Counter (OTC) Analgesics Market Overview

13
1.1 Statistics at a Glance: The Scenario of Over The Counter (OTC) Analgesics
in the World
Scope of Over The Counter (OTC)
Analgesics
▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In this section you will get an
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
topic
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
$26,298.79 Mn
The over-the-counter (OTC)
analgesics market was
valued in 2021
$33,640.61 Mn
The over-the-counter
(OTC) analgesics market
is expected to reach by
2027
73.68%
of all deaths accounting
by Chronic or Non-
communicable diseases
2.3 Mn
women diagnosed with
breast cancer and
685,000 deaths globally,
in 2020

14
1.1 Statistics at a Glance: The Burden of Over The Counter (OTC) Analgesics
Market in the World (continued)
North America
~ Market Size of
$xx Bn
Europe
~Revenue to reach
$xx Bn by 2027
Asia
-Fastest CAGR
Africa
~Market Size of $xx
Turkey Market
~$xx Market
Illustrative

15
1.2 Turkey Overview
84.8 Mn
Is the population of
Turkey, in 2023
30.6
Is the median age
in Turkey, in 2022
$819.03 Bn
Is the Gross
Domestic Product
(GDP) in Turkey in
2021
$9.6 k
per capita was the
amount of national
health expenditures in
2021
report
understanding of the demographics of the
country/region, which includes the
population, GDP, healthcare expenditure
and other details related to the topic
interest

16
1.3 Economic Overview: Turkey
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population of Turkey, (2020-2030)
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
GDP of Turkey, (2020-2030)
Population Split (2023)
55-64
0-14
15-24
25-54
65+
Male
49%
Female
51%
By Age Group
By Gender
▪ In this section you will get an understanding of the demographics
of the country/region, which includes the population, GDP,
healthcare expenditure and other details related to the topic
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

17
1.4 Statistics at a Glance: The Scenario of Over The Counter (OTC) Analgesics
in Turkey
Scope of Over The Counter (OTC)
Analgesics ▪ Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the topic, which
includes the prevalence of the disease,
the application of medical devices, new
technology, and other details related to
the topic in Turkey
information that you are seeking, you
will need to purchase the final report
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
$194.80 Mn
Revenue in the OTC
Analgesics market in
Turkey amounts to
$194.80 Mn in 2023
7.84%
The Turkey market is
anticipated to expand by
7.84% yearly (CAGR 2022-
2030)
$84.48 Mn
With a market
volume of $84.48
Mn in 2023,
analgesics will be
the Turkey OTC
market's largest
section
1 in 5
By 2023, internet sales in
Turkey's OTC
pharmaceuticals sector will
account for 19.2% of total
revenue

18
1.5 Pharmaceuticals in Turkey
xx xx xx xx xx xx xx xx xx
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Turkey Pharmaceuticals Market Forecast, 2022-2030 (in $Bn)
▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be
presented in the final report
▪ In this section you will get an understanding of the overall Pharmaceuticals market in Turkey, which includes the market size, current trends
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or
Illustrative

19
1.6 Healthcare Scenario in Turkey
Cancer Drug Development Process: The process of developing a cancer drug is complex and involves many stages, from preclinical research
to clinical trials to regulatory approval. Here is a simplified diagram of the cancer drug development process:
o Preclinical Research: Researchers identify potential drug candidates and test them in the lab
o Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans
o Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating cancer
o Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and
effectiveness
o Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market
Fast Track
▪ Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat
serious conditions and fill an unmet medical need
Breakthrough
Therapy
▪ A process designed to expedite the development and review of drugs which may demonstrate substantial
improvement over available therapy
Accelerated
Approval
▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved
based on a surrogate endpoint
Priority Review ▪ A Priority Review designation means FDA’s goal is to take action on an application within 6 months
FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and
effectiveness. Here are four of these approaches:
Illustrative

20
1.6 Healthcare Scenario: Patient Journey
Presentation Diagnosis Treatment Follow up
A suspected diagnosis is
usually made, based on
physical examination and
detailed patient and family
history
Prenatal screening/
Neonatal screening
Initial Diagnosis
Complete blood count
(evaluate number &
quality of RBCs, Hb &
WBCs)
Imaging (confirm bone
related changes or
respiratory problems)
Bacterial cultures of
blood, sputum, urine,
stool (detect any
infection)
Genetic testing (detect
the type of SCD)
Confirmatory Diagnosis
Prevention and management of
crisis:
• For VOC and Splenic
Sequestration: HU, Endari,
Adakveo, Oxbryta
• For infections: Antibiotics,
Vaccines
Prevention and management of
complications:
• Stroke: Chronic transfusions, HU
• Long term follow-up is required for
patients with SCD
• Annual assessment: CBC and
reticulocyte count, iron status, liver
and renal function tests, urinalysis,
LDH, vitamin D level and
neurocognitive assessment
• ESOD (End Stage Organ Damage)
evaluation starting from age 7
• Yearly Transcranial Doppler test to
determine risk of stroke
Stakeholders
PCP, paediatrician,
neonatologist,
haematologist and genetic
counsellor
PCP, pediatrician, medical geneticist,
hematologist, gynecologist and pathologist
PCP, pediatrician, medical geneticist,
cardiologist, hematologist,
endocrinologist, psychologist and
psychiatrist
PCP, pediatrician, neonatologist,
endocrinologist, cardiologist,
hematologist, orthopedist, psychologist
and psychiatrist
Depending on the organ complications,
the treatment involves different
specialists at different times
Illustrative

21
1.7 Health Insurance Coverage: Egypt
1.0
18.9
18.4
35.7
2.5
3.5
10.2
54.3
66.0
91.7
8.3
VA and CHAMPVA
Medicaid
Medicare
Any public plan
TRICARE
Marketplace
Direct-purchase
Employment-based
Any private plan
With health insurance
Uninsured
▪ In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire
calendar year
▪ More people had private health insurance (66%) than public coverage (35.7%)
▪ Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%),
followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care
(1%)
Coverage Type 2020 2021 Change %
Total 327,521 328,074
Any health plan 299,230 300,887 0.4
Any private plan 217,896 216,366 –0.6
Employment-based 178,737 178,285 –0.2
Direct-purchase 33,869 33,555 –0.1
Marketplace coverage 10,924 11,389 0.1
TRICARE 9,165 8,299 –0.3
Any public plan 112,925 117,095 1.2
Medicare 58,541 60,226 0.5
Medicaid 58,778 61,940 0.9
VA and CHAMPVA 2,967 3,151 0.1
Uninsured 28,291 27,187 –0.4
% of People by Type of Health Insurance Coverage
(2021)
Number of People By Health Insurance Coverage
Illustrative

22
1.8 Budget of Turkey Government for Public Insurance
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Medicare $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
Medicaid $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926
As % Of GDP
Medicare 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
Medicaid 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4%
▪ National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE
▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE
▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE
▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE
▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE
▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020
▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020
▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020
▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health
spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative

23
1.9 Mergers and Acquisitions
$6.0
$7.7
$10.5
$16.7
$6.8
$11.7
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
82
112 107 107
89
110
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020
RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend
Buyer Composition: Strategic Vs Financial (2020)
59%
41% 41%
59% 58%
42%
61%
39%
$0- $25 $25-$50 $50-$100 $100+
Strategic Buyers
Financial Buyers
Buyer Type by Deal Size
($Mn)
Illustrative

24
1.9 Mergers and Acquisitions (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Oracle acquisition of
Cerner
Acquisition $28.3 Bn June, 2022
▪ Oracle’s acquisition of Cerner is big tech’s latest foray into the
healthcare system, promising better outcomes
▪ Oracle acquire Cerner through an all-cash tender offer for $95.00
per share, or approximately $28.3 Bn in equity value
▪ Cerner is a leading provider of digital information systems used
within hospitals and health systems to enable medical
professionals to deliver better healthcare to individual patients
and communities
GSK acquisition of
BELLUS Health
Acquisition $2 Bn April 2023
▪ GSK has acquire BELLUS for US$14.75 per share of common
stock in cash representing an approximate total equity value of
US$2.0 billion
▪ BELLUS is a late-stage biopharmaceutical company working to
better the lives of patients suffering from persistent cough
▪ Acquisition further strengthens specialty medicines and
respiratory pipeline with camlipixant, a highly selective P2X3
antagonist and potential best-in-class treatment for refractory
chronic cough
Latest Deals In Turkey
Illustrative

25
1.9 Mergers and Acquisitions (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Merger March 2023
Merger Jan 2023
Latest Deals In Turkey
Illustrative

2. Market Size and Forecasting

27
2.1 Market size and forecasts (Excel and Methodology)
XX
XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Turkey Over The Counter (OTC) Analgesics Market Forecast, 2022-
2030 (in $Bn)
▪ Please be aware that this sample report
final report
understanding of the overall Healthcare
Insurance market in Malaysia, which
includes the market size, current trends
Click on the icon to know the
methodology and assumption
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient
(Mn)
2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
Turkey Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of US Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
Turkey Market Size (Bn $) 61 74 84 87 91 95 99 106
Illustrative

28
2.2 Snapshot of Turkey Over The Counter (OTC) Analgesics Market
Segmentation
▪ In this section you will get an understanding of the segmentations which will cover the Turkey Over The Counter (OTC) Analgesics
Market
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
By Product By Distribution Channel
Analgesics
Cold & Cough Remedies
Digestive and Intestinal Remedies
Drug Stores and Retail
Pharmacies
Hospital Pharmacies
Online Pharmacies

29
Turkey Over The Counter (OTC) Analgesics Market Share, By
Product Type (2022)
▪ Analgesics market in Turkey is a
significant component of the overall
treatment market
▪ It has the maximum market share in
Turkey Over The Counter (OTC)
Analgesics Market with approximately
xx%
final report
2.2.1 Market Segmentation: By Product
Analgesics
Breast Cancer
Cold & Cough
Remedies

30
Turkey Over The Counter (OTC) Analgesics Market Share, By
Distribution Channel (2022)
2.2.2 Market Segmentation: By Distribution Channel
▪ Drug Stores and Retail Pharmacies
market in Turkey is a significant
component of the overall treatment
market
final report
Drug Stores and
Retail
Pharmacies
Hospital
Pharmacies
Online
Pharmacies

3. Market Dynamics

32
3.1 Market growth drivers
▪ Chronic diseases often come with symptoms such as persistent
pain or discomfort. Conditions like arthritis, fibromyalgia, or
chronic back pain can cause long-term pain that requires ongoing
management
▪ As the prevalence of these chronic diseases rises, the demand for
OTC analgesics also increases to help individuals manage their
pain and improve their quality of life
▪ Please be aware that this sample report is intended to provide you
with a brief overview of the kind of information and analysis that
will be presented in the final report
▪ Final report will be comprehensive and detailed, and it will include
data, analysis, trends, and other relevant information related to the
topic or subject matter of interest 2010 2022 2030
3.1.1 The point prevalence of low back pain in Turkey was found to be 20.1% - 19.7% in 2021 whereas the lifelong
occurrence was found to be 44% - 79%, which leads to market expansion for Turkey Over The Counter (OTC)
Analgesics
Incidence of Chronic diseases in Turkey
Illustrative

33
3.1 Market growth drivers (continued)
Top countries by incidence of breast
cancer
United States
Japan
Germany
South Korea
China
United Kingdom
France
Canada
Australia
Israel
Switzerland
Singapore
Sweden
Netherlands
Italy
Spain
Belgium
Denmark
Austria
Norway
Illustrative
3.1.2 Turkey experienced an increase in the incidence of breast cancer in 2021, as more than 15,687 new cases were
found there. The market for over-the-counter (OTC) analgesics in Turkey has expanded as a result
▪ OTC analgesics, such as acetaminophen (paracetamol) and
nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, can
be used to manage pain associated with breast cancer
▪ In breast cancer, pain can occur due to various reasons, including
surgical procedures, radiation therapy, chemotherapy-induced
side effects, or the cancer itself
▪ OTC analgesics can provide relief from mild to moderate pain
associated with these factors
▪ Final report will be comprehensive and detailed, and it will include
data, analysis, trends, and other relevant information related to the
topic or subject matter of interest

34
3.2 Market restraints
3.2.1 In 2023, Around 89 persons per
day in Turkey pass away from OTC
analgesic overdoses
▪ In extreme situations, overdosing on
over-the-counter (OTC) analgesics can
result in life-threatening complications,
including death
▪ It is imperative to emphasize that over-
the-counter pain killers should only ever
be used as prescribed and within the
recommended dosage ranges
3.2.2 Average cost of developing a new
Over The Counter (OTC) Analgesics that
is ultimately approved by the TMMDA is
over $2303.95
▪ Regulatory requirements for OTC
Analgesics can be very stringent, which
can slow down the approval process
and limit access to new treatments
▪ Regulatory bodies, such as Turkey
Medicines and Medical Devices
Authority (TMMDA), require extensive
clinical trials and safety data before
approving new OTC analgesics
▪ This can be a lengthy and costly
process, which can delay the
availability of new treatments for
patients
3.2.3 Demand for Over The Counter
(OTC) Analgesics is expected to
increase by 52.88% by 2025, while the
supply of Over The Counter (OTC)
Analgesics is only expected to increase
by 32.79%
▪ There is a shortage of Over The
Counter (OTC) Analgesics in Turkey,
which can limit access to treatments
and create barriers to growth in the
Over The Counter (OTC) Analgesics
market
▪ With the aging population and the
increasing incidence of disease, there
is a growing demand for Over The
Counter (OTC) Analgesics
▪ However, the supply of Over The
Counter (OTC) Analgesics is not
keeping pace with the demand
Our analysis will thoroughly investigate the key restraints that may significantly impact bTurkeyiness
operations and growth.
Illustrative

4. Competitive Landscape

36
4.1 Major Market Share
XX
Other
▪ Turkey Over The Counter (OTC)
Analgesics market is a highly competitive
space, with many companies developing
and marketing treatments
▪ Some of the top companies in Turkey Over
The Counter (OTC) Analgesics market
based on revenue and market share
include
▪ Sanovel Pharmaceuticals is a Swiss
multinational healthcare company that
develops and markets cancer treatments,
including targeted therapies and
immunotherapies
▪ In 2020, Sanovel Pharmaceuticals's
oncology sales were approximately $24
Bn, making it one of the largest players in
Turkey Over The Counter (OTC)
Analgesics market
Revenue of Major players in Turkey Over The Counter
(OTC) Analgesics($ Mn)
Illustrative

37
4.2 Key Company Profile
▪ Here is the list of top 10 companies which
will cover in the final report
▪ Each company will have slides for
o Overview
o Key details
o Offerings
o Name of products
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
o Mergers, Acquisitions and
Collaboration
o Financials
▪ If there are specific companies that you
would like to be included in the report,
please let Turkey know via email
1 Sanovel Pharmaceuticals
3
Abdi Ibrahim Ilac Sanayi ve
Ticaret
5 GlaxoSmithKline
7 Bayer AG
9 Pfizer
2 Bilim Pharmaceuticals
4 Novartis
6 Johnson and Johnson
8 Reckitt Benckiser Group
Bohringer Ingelheim
International
10
Key Note:

38
4.2.1 Sanovel Pharmaceuticals
Founded in: 1983
HQ: Istanbul, Turkey
Type: Private
Revenue: $18.7 Mn
Website: www.sanovel.com
▪ Sanovel Pharmaceuticals is a pharmaceutical company that
develops and produces medications, including those used to treat
cancer
▪ Several over-the-counter analgesics are available from Sanovel
Pharmaceuticals to relieve pain and discomfort. These medications
are made to treat a variety of pains, including menstruation
discomfort, joint pain, migraines, and muscular aches
▪ They might be offered in tablets, capsules, or creams, among other
forms
Solutions offered by Sanovel
Pharmaceuticals
➢ Diagnostics
➢ Pharmaceuticals
➢ Healthcare Software
➢ Clinical Trials
➢ Patient Support
Recent Activity / Press Coverage
▪ Toksöz Group of Turkey has paid Yamma Investments of Luxembourg $200 Mn for a 30% stake in the pharmaceutical company Sanovel
▪ Sanovel Pharmaceuticals launches two new antibodies to identify key clinical mutations in patients with breast cancer
▪ Parent company Toksoz Holding has put Turkish generic drug maker Sanovel up for sale, and it might bring in between $500 Mn to $1 Mn

39
4.2.1 Sanovel Pharmaceuticals (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
One of the largest pharmaceutical
distributors in the United States, McKesson
has been a long-standing distribution
partner for Sanovel Pharmaceuticals
Cardinal Health is a Fortune 500 healthcare
services company that provides
pharmaceutical distribution services to
Sanovel Pharmaceuticals
It is one of the largest drugstore chains in
the United States and Europe, and its
extensive network of retail locations and
distribution centers make it an important
distribution partner for Sanovel
Pharmaceuticals
A leading healthcare services provider in
Asia, Zuellig Pharma is a distribution
partner for Sanovel Pharmaceuticals in
several Asian countries
One of the largest pharmaceutical
wholesalers in Europe, PHOENIX Group
distributes Sanovel Pharmaceuticals's
products in several European countries
Sanovel Pharmaceuticals has been working
with SAP, a leading software company, to
develop digital solutions for its healthcare
products
A leading Swiss biotechnology company,
Lonza provides Sanovel Pharmaceuticals
with contract manufacturing services for the
production of its biologics and
pharmaceuticals
Sanovel Pharmaceuticals has a strategic
partnership with Microsoft to leverage its
cloud computing and AI technologies in the
development of new healthcare products
Thermo Fisher Scientific is a leading
provider of analytical instruments, reagents,
and laboratory services
GE Healthcare provides Sanovel
Pharmaceuticals with advanced medical
imaging and diagnostics technologies,
including CT scanners and MRI machines
Illustrative

40
Company Name Type
Amount /
Duration
Year Key Pointers
Lilly
Collaboration - March, 2023
▪ Sanovel Pharmaceuticals and Lilly will collaborate on the
development of Sanovel Pharmaceuticals Diagnostics’ Elecsys
Amyloid Plasma Panel
▪ Elecsys Amyloid Plasma Panel has demonstrated clinical
performance and is currently undergoing additional investigation
to ensure clinical validation
▪ Once approved, could help healthcare professionals to streamline
the journey to diagnosis for more patients
GenMark Diagnostics
Merger $1.8 Bn March 2021
▪ Sanovel Pharmaceuticals to acquire GenMark Diagnostics for
US$ 24.05 per share with the expectation to close in the 2nd
quarter of 2021
▪ GenMark provides molecular diagnostic tests that are designed to
detect multiple pathogens from a single patient sample
▪ GenMark’s ePlex platform delivers rapid and actionable results so
clinicians can determine the cause of infection and the most
effective treatment, potentially saving lives and alleviating the
healthcare burden
Latest Deals - Mergers and Acquisitions
Illustrative

41
63.3
70.3 70.9
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
▪ According to Sanovel Pharmaceuticals
2020 financial report, the company had
sales of CHF 56.65 Bn (Swiss Francs) in
2020
▪ This is equivalent to approximately $63.3
Bn USD, based on exchange rates at the
end of 2020
▪ Company's Pharmaceuticals Division
generated sales of CHF 49.9 Bn in 2020,
while the Diagnostics Division generated
sales of CHF 8.4 Bn
▪ Revenue generated by Sanovel
Pharmaceuticals in 2020 reflects the
company's continued growth and success
in the healthcare industry
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

42
4.2.2 Company 2
Founded in:
HQ:
Type:
Revenue:
Website:
Solutions offered by Company
Drugs Indications
Drugs for Cancer Recent Activity / Press Coverage
Illustrative

43
4.2.2 Company 2 (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
Illustrative

44
Company Name Type
Amount /
Duration
Year Key Pointers
Latest Deals - Mergers and Acquisitions
Illustrative

45
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

5. Reimbursement Scenario

47
5.1 Reimbursement Regulation
The reimbursement scenario in the Turkey Over The Counter (OTC) Analgesics
market is complex and can vary depending on the specific treatment, setting of
care, and insurance coverage. Here are some key points to consider:
▪ Medicare:
o Medicare is a federal health insurance program for people aged 65 and
older, as well as people with certain disabilities or health conditions
o Medicare covers many cancer treatments, including chemotherapy,
radiation therapy, and some immunotherapies
o However, coverage can be subject to strict guidelines and restrictions,
such as the requirement for prior authorization
▪ Medicaid:
o Medicaid is a joint federal-state program that provides health insurance
for people with low incomes
o Medicaid coverage for cancer treatments can vary by state, and may be
subject to limits on the amount and type of treatment covered
▪ Private Insurance:
o Private insurance coverage for cancer treatments can also vary widely
depending on the insurer and the specific policy
o Some policies may have high out-of-pocket costs, such as deductibles
and co-pays, while others may have more comprehensive coverage
Medicare and Medicaid together provide
health insurance coverage for more than
4 in 10 Americans
Medicare
17%
Medicaid
and CHIP
21%
Employer-Sponsored
49%
Other Private
3%
Other Public
1%
Uninsured
9%
Health Insurance Coverage, 2022
Illustrative

48
5.1 Reimbursement Regulation (continued)
▪ Affordable Care Act:
o Affordable Care Act (ACA) includes provisions to help improve access to cancer treatments by requiring insurers to cover
certain preventive services, including cancer screenings, without co-pays or deductibles
o It also includes protections for people with pre-existing conditions, such as cancer
▪ Reimbursement for New Treatments:
o Reimbursement for new cancer treatments can be a complex and lengthy process, as insurers and government programs
often require evidence of safety and effectiveness before providing coverage
o This can create challenges for companies developing and marketing new treatments
▪ Value-Based Care:
o There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the
value of treatments rather than simply the volume of treatments
o Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
Illustrative

49
5.1 Reimbursement Regulation (continued)
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
 Public healthcare coverage is provided by the government and includes programs like
Medicare and Medicaid
 Medicare is a federal program that provides healthcare coverage to individuals who
are 65 years of age or older, as well as certain younger people with disabilities
 Medicaid is a joint federal-state program that provides healthcare coverage to
individuals with low income and limited resources
▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care 38.9%
37.1%
35.6%
32.5%
31.5%
44.0%
46.0%
47.7%
51.0%
51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx xx xx xx xx
2012 2013 2014 2015 2016
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative

50
5.2 Reimbursement Process
The reimbursement process in the Turkey healthcare system can be complex and can vary depending on the type of healthcare
service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the
service provided
▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for
reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential
errors or fraud
▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service
provided, based on the negotiated payment rates or fee schedule
▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost
of the service, such as deductibles, co-payments, or co-insurance
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
Illustrative

51
5.3 Reimbursement Process
The reimbursement process in the US healthcare system can be complex
and can vary depending on the type of healthcare service, the healthcare
provider, and the insurance coverage. Here are the general steps involved
in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a
service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance
company or other payer, requesting reimbursement for the service
provided
▪ Adjudication: The insurance company or other payer reviews the claim
to determine whether it meets the criteria for reimbursement. This can
involve verifying the patient's eligibility, reviewing the treatment
provided, and checking for any potential errors or fraud
▪ Payment: If the claim is approved, the insurance company or other
payer reimburses the healthcare provider for the service provided,
based on the negotiated payment rates or fee schedule
FDA
Private Payers Public Payers
Health Technology Assessment
Payment
Coverage
Coding
Coding depends on availability code while coverage and
payment process decisions are made through an HTA.
Market Authorization
1 3
2
Illustrative

6. Methodology & Scope

Research Methodology
▪ Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the
key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive
overview of the competitive landscape to help our clients make informed strategic decisions
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government
and regulatory published material, technical journals, trade magazines, and paid data sources
▪ For forecasting, the following parameters are considered:
❑ Market drivers and restraints along with their current and expected impacts
❑ Technological scenario and expected developments
❑ End use industry trends and dynamics
❑ Trends in the consumer behavior
❑ Regulatory scenario and expected developments
❑ Current capacity and expected capacity additions up to 2030
▪ We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected
market growth rate
▪ We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
▪ All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪ Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)
Illustrative

Analysis Methodology
Our Analysis Methodology involves three critical stages:
Market Trends
Market Sizing &
Analysis
Data Triangulation &
Validation
Analysis &
Interpretation
Insights
Presentation &
Reporting
Market Data Analysis
& Statistical Model
Interpretation &
Presentation
Secondary
Research
Proprietary
Database
Data
Collection
Primary
Research

Data Triangulation & Data Validation
Bottom Up Approach
Summarization of revenue
generated from companies
to arrive at total market size
Revenue generated by products &
services offered by companies
Validation from
Primary Interview
Final
Market
Size
Top Down Approach
Final Market size break up to
rest of segmentation
Arriving at market size
of each segment
Validation from
Primary Interview
Final
Summary

Key Benefits for Stakeholders from this Report
Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent
investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2022 to 2030F is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors

2022
2023-
2030
Report Attribute
Quantitative Units
Report Coverage
Customized Report
Pricing and purchase
options
Revenue in USD Million/Billion (Mn/Bn)
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (3 to 5 working days)
with purchase. We will provide you with data
that is currently not a part of our scope as a
part of customization
Avail customized purchase options to meet
your exact research needs
Details
Time Frame
Base Year for
Estimation
Forecast
Period

Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
www.insights10.com
Lifesciences Market
Research Reports you
can trust

www.insights10.com
A large database of over 30,000 syndicated
market research reports in Pharmaceuticals and
healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Get actionable insights to
take informed business
decisions

Our qualitative, acute, and result-oriented market
research reports provide a comprehensive
understanding of the business scenario and the
latest trends related to the life sciences market
Elevate your business plans
with in-depth market analysis
and industry intelligence
www.insights10.com

Whether you are looking to expand into new
areas, develop new products, or take advantage
of new opportunities we have reports to help you
accelerate and improve your plans by identifying
unique growth prospects.
Gain a competitive edge with
Insights10's customized
healthcare research solutions
www.insights10.com

Healthcare
Services
Clinical
Trials
OTC &
Nutraceuticals
Pharmaceuticals
(Diseases & Drugs)
Digital
Health
Medical
Devices
across various categories
Market Research Reports

FEATURED REPORTS FREE SAMPLE REPORTS
TRENDING TOPICS

1200+
Reports
Published
Annually
30000+
Life science
Market Research
Reports
22000+
Country
Specific
Reports
2000+
Rare & orphan
Disease
Reports
What makes us different?

Market Overview
Growth Drivers &
Growth Restraints
Market Segmentation
Market Share Factors Driving Future Growth
Reimbursement Scenario
Policy & Regulatory
Landscape
Key Company Profiles
Epidemiology &
Disease type
Competitive Landscape
insights on
which our
reports are
based
1
2
3
4
5
6
10
9
8
7
Table of Contents

Subscription
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database
Service
Primary
Research
Customized
Reports
Market Research
Reports
Our Services

Research Projects Done
Over the years, we have developed an in-depth experience of executing
market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions

Our Research Process
01 03
02 04 05
Identification of
Data
Collection of
Data
Market
Dynamics
Collaboration
of Data
Verification &
Analysis

Statistical Databases
Data
Sources
We have access to multiple highly
reliable free and subscription data
sources. We have many years of
experience to understand which
sources are more dependable for what
and which to prefer for the reliable and
latest information.
Company Websites/Annual Reports
Trade Publications
Online Databases
Published Research Reports
Whitepapers
Press Releases of Key Market Players

What kind of data is presented
in our reports?
Our reports present data, which is:
The report is
prepared using a
proven methodology
and insightful
research
Reliable
The data is prepared
by a team of highly
qualified &
experienced research
analysts & vetted by
our local associates
Expert-verified
Allowing you to
confidently make
smarter business
and strategic
decisions
Real
Covers everything
you would need to
know about the
market including
market size,
competitive analysis
& much more
Comprehensive
You do not have to
be a market expert
to understand what
really is happening
on the market and
how it works
Easy to read

“The business decision-making process is no longer as
straightforward as it used to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market.
We at Insights10 are building the future of market
research and are committed to providing our clients with
the right intelligence and insights to make business
decisions quickly and efficiently.
Insighs10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working
with some of the best organizations in the world,
generating insights that provides substantial competitive
advantage.”
Dr. Purav Gandhi
Founder & CEO

Purav is a physician and an entrepreneur
with 12+ years of experience in Healthcare
& Life Sciences industry spanning across
strategy, market access, health informatics
and RWE, digital health, analytics and data
science. Purav studied medicine from
Gujarat University and also completed his
MBA from IIM-Kozhikode. Purav started
his career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of experience
in management consulting in the
Life Sciences sector, and has
worked with diverse multinational
firms in the US, India, Middle East
and APAC regions. His primary
area of interest is Customer and
Market Strategy, Market Access,
and Digital Health with special
focus on emerging markets like
Africa, Middle East and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Leadership Team
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research & marketing
professional with a progressive
experience of over 20 years in Life
Sciences, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across diff.
markets (America, Europe, Africa, APAC
and Middle East). Her areas of expertise
include: Indentifying emerging trends in life
sciences industry, Competitor landscape
assessment, Disease opportunity
assessments etc. She is a pro in secondary
and primary research with a deep domain
expertise in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager

Web: www.insights10.com
Email: insights@insights10.com
Call: (+91) 931 639 7935
WhatsApp: (+91) 931 639 7935
We would be happy to help.
Do you have
any questions?

www.insights10.com
Thank you
We truly appreciate your business and
look forward to serving you.

Turkey Over The Counter (OTC) Analgesics Market Analysis Sample Report

Recommended

Recommended

More Related Content

Similar to Turkey Over The Counter (OTC) Analgesics Market Analysis Sample Report

Similar to Turkey Over The Counter (OTC) Analgesics Market Analysis Sample Report (20)

More from Insights10

More from Insights10 (20)

Recently uploaded

Recently uploaded (20)

Turkey Over The Counter (OTC) Analgesics Market Analysis Sample Report